There are many treatments for endometrial cancer, and the choice of treatment will depend on the extent (stage) of your disease along with other things. Jemperli is a treatment for endometrial cancer.

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer. Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK ...

GSK plc GSK announced positive interim data from part 1 of the phase III RUBY study which evaluated Jemperli (dostarlimab) in first-line endometrial cancer. Part 1 of the RUBY study evaluated ...

Endometrial cancer is a type of cancer that starts in ... Checkpoint inhibitors like dostarlimab (Jemperli) pembrolizumab (Keytruda) and block a protein called PD-1 on immune cells.

The tolerability and safety profile for Jemperli combined with carboplatin-paclitaxel was consistent with the known safety ...

FDA approval for Jemperli plus chemotherapy was expanded to include all adult patients with primary advanced or recurrent endometrial cancer in August 2024. More on GSK GSK plc (GSK) 43rd Annual J ...

GSK’sGSK-0.21%decrease; red down pointing triangle cancer drug Jemperli cleared an important ... of adult patients with primary or recurrent endometrial cancer who are candidates for systemic ...